Saturday, October 31, 2026

Julian Assange Releases a Statement Saying Wikileaks is Not Trying to Influence U.S. Elections

Julian Assange's legal advisor Juan Branco released a statement at Web Summit 2016 in Lisbon denying WikiLeaks intended to influence the US election. Assange maintained that the Clinton-related leaks met WikiLeaks' editorial criteria and served the public interest.

LM Salvado
LM Salvado

November 9, 2016

Julian Assange Statement
Juan Branco, Julian Assange’s legal advisor released a statement during the Web Summit, the world’s leading technology event taking place in Lisbon. Juan Branco participated in the talk "Should the Internet be a safe place?" in the "Future Societies" stage with Salil Shetty from the Amnesty International, Laurie Penny (New Statement), Rabia Chaudry from Adnan's Story and the artist Helly Luv. Following his talk, Juan Branco released the Julian Assange statement saying WikiLeaks publication of material linked to Hillary Clinton was not based on any desire to influence the U.S. election. Julian Assange said in the statement that recently, WikiLeaks and he have been under pressure not to publish "what the Clinton campaign says about itself to itself". He stated that the "pressure has come from the campaign's allies, including the Obama administration, and from liberals who are anxious about who will be elected US President." Mr. Assange pointed out that "Irrespective of the outcome of the 2016 US Presidential election, the real victor is the US public which is better informed as a result of our work." The information WikiLeaks leaks had that fit the editorial criteria related to the Sanders and Clinton campaign (DNC Leaks) and the Clinton political campaign and Foundation (Podesta Emails) had to, according to Julian Assange, be released. "No-one disputes the public importance of these publications. It would be unconscionable for WikiLeaks to withhold such an archive from the public during an election." Regarding the alleged missing leaks about Donald Trump, Mr. Assang said: "At the same time, we cannot publish what we do not have. To date, we have not received information on Donald Trump's campaign, or Jill Stein's campaign, or Gary Johnson's campaign or any of the other candidates that fulfill our stated editorial criteria." "We have endured intense criticism, primarily from Clinton supporters, for our publications. Many long-term supporters have been frustrated because we have not addressed this criticism in a systematic way or responded to a number of false narratives about Wikileaks’ motivation or sources. Ultimately, however, if Wikileaks reacted to every false claim, we would have to divert resources from our primary work.", he said. Assange has been living in Ecuador's London embassy since 2012.

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com